Can Trastuzumab Therapy Continue After LVEF Decline in HER2+ Breast Cancer?

The researchers looked at cardiac outcomes among a group of HER2+ breast cancer patients treated with trastuzumab who had an asymptomatic LVEF decline of< 50%.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news